Continue to site >
Trending ETFs

Name

As of 05/17/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

$19.23

$11 M

1.16%

$0.22

0.68%

Vitals

YTD Return

-1.4%

1 yr return

-5.5%

3 Yr Avg Return

-19.2%

5 Yr Avg Return

N/A

Net Assets

$11 M

Holdings in Top 10

77.0%

52 WEEK LOW AND HIGH

$19.5
$15.76
$21.28

Expenses

OPERATING FEES

Expense Ratio 0.68%

SALES FEES

Front Load N/A

Deferred Load N/A

TRADING FEES

Turnover 39.00%

Redemption Fee N/A


Min Investment

Standard (Taxable)

$0

IRA

N/A


Fund Classification

Fund Type

Exchange Traded Fund


Name

As of 05/17/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

$19.23

$11 M

1.16%

$0.22

0.68%

GERM - Profile

Distributions

  • YTD Total Return -1.4%
  • 3 Yr Annualized Total Return -19.2%
  • 5 Yr Annualized Total Return N/A
  • Capital Gain Distribution Frequency N/A
  • Net Income Ratio 0.98%
DIVIDENDS
  • Dividend Yield 1.2%
  • Dividend Distribution Frequency Quarterly

Fund Details

  • Legal Name
    ETFMG Treatments Testing and Advancements ETF
  • Fund Family Name
    ETF Managers Trust
  • Inception Date
    Jun 17, 2020
  • Shares Outstanding
    1200000
  • Share Class
    N/A
  • Currency
    USD
  • Domiciled Country
    US
  • Manager
    Devin Ryder

Fund Description

The Fund uses a “passive” or indexing approach to try to achieve the Fund’s investment objective. Unlike many investment companies, the Fund does not try to “beat” the Index and does not seek temporary defensive positions when markets decline or appear overvalued.
The Fund will use a replication strategy. A replication strategy is an indexing strategy that involves investing in the securities of the Index in approximately the same proportions as in the Index. However, the Fund may utilize a representative sampling strategy with respect to the Index when a replication strategy might be detrimental to shareholders, such as when there are practical difficulties or substantial costs involved in compiling a portfolio of equity securities to follow the Index, in instances in which a security in the Index becomes temporarily illiquid, unavailable or less liquid, or as a result of legal restrictions or limitations (such as tax diversification requirements) that apply to the Fund but not the Index. The Fund rebalances its portfolio in accordance with its Index, and, therefore, any changes to the Index’s rebalance schedule will result in corresponding changes to the Fund’s rebalance schedule.
The Fund invests at least 80% of its total assets, exclusive of collateral held from securities lending, in the component securities of the Index. The Fund may invest up to 20% of its total assets in securities that are not in the Fund’s Index to the extent that the Fund’s adviser believes such investments should help the Fund’s overall portfolio track the Index. The Fund may also invest in other investment companies that principally invest in the types of instruments allowed by the investment strategies of the Fund.
The Fund may lend its portfolio securities to brokers, dealers, and other financial organizations. These loans, if and when made, may not exceed 33 1/3% of the total asset value of the Fund (including the loan collateral). By lending its securities, the Fund may increase its income by receiving payments from the borrower.
Prime Treatments, Testing and Advancements Index
The Index tracks the performance of U.S.-listed equity securities or depositary receipts of companies that (i) perform research, development, and commercialization of treatments or vaccines for infectious diseases or (ii) engage in the research, development,
manufacturing, and provision of biological tests for patients. Such companies are identified by Prime Indexes (the “Index Provider”), an independent index provider that is not affiliated with the Fund’s investment adviser, based on the rules of the Index.
The Index is comprised of two groups of companies, as described below: “Treatment Companies” and “Testing Companies”. “Treatment Companies” are companies that (i) have one or more vaccines or treatments for infectious diseases in pre-clinical research, in any phase of U.S. Food and Drug Administration clinical trials, or in a commercial stage and (ii) are classified by the North American Industry Classification System as either “Pharmaceutical and Medicine Manufacturing” or “Research and Development in the Physical, Engineering, and Life Sciences”. “Testing Companies” are companies that derive more than 50% of their revenue from the research, development, manufacturing, and provision of biological tests for patients.
To qualify for inclusion in the Index, Treatments Companies and Testing Companies must have an operating company structure (as opposed to being a pass-through security). To be added to the Index, Treatments Companies and Testing Companies must have a minimum market capitalization of US$100 million and an average daily value traded over the prior three month period of $250,000. Companies already included in the Index must have a minimum market capitalization of US$50 million.
The Index has a quarterly review in each March, June, September, and December, at which times the Index is reconstituted and rebalanced by the Index Provider. The composition of the Index and the constituent weights are determined on the two Thursdays before the second Friday of each March, June, September, and December (or the next business day if this is a non-business day). Component changes are made after the market close on the third Friday of each March, June, September, and December (or the next business day if the third Friday is not a business day) and become effective at the market opening on the next trading day.
The five largest constituents with a market capitalization under US$15 billion are each weighted at 6% (30% in the aggregate). The remaining constituents with a market capitalization under US$15 billion are weighted bases on their market capitalization subject to a 4% limit per security. Constituents with a market capitalization of US$15 billion or more will be equally weighted with an aggregate weighting of 10%.
The Index is developed and owned by Prime Indexes, and the Index is calculated and maintained by Solactive AG. The Index Provider is not affiliated with Solactive AG, the Fund, or the Fund’s investment adviser.
As of January 10, 2023, the Index had 68 components.
The Fund will concentrate its investments (i.e., hold more than 25% of its net assets) in a particular industry or group of related industries to approximately the same extent that the Index is concentrated. As of January 10, 2023, the Index was concentrated in the biotechnology industry.
The Fund rebalances its portfolio in accordance with its Index, and, therefore, any changes to the Index’s rebalance schedule will result in corresponding changes to the Fund’s rebalance schedule.
Correlation: Correlation is the extent to which the values of different types of investments move in tandem with one another in response to changing economic and market conditions. An index is a theoretical financial calculation, while the Fund is an actual investment portfolio. The performance of the Fund and the Index may vary somewhat due to transaction costs, asset valuations, foreign currency valuations, market impact, corporate actions (such as mergers and spin-offs), legal restrictions or limitations, illiquid or unavailable securities, and timing variances.
The Fund’s investment adviser expects that, over time, the correlation between the Fund’s performance and that of the Index, before fees and expenses, will exceed 95%. A correlation percentage of 100% would indicate perfect correlation. If the Fund uses a replication strategy, it can be expected to have greater correlation to the Index than if it uses a representative sampling strategy.
Read More

GERM - Performance

Return Ranking - Trailing

Period GERM Return Category Return Low Category Return High Rank in Category (%)
YTD -1.4% -19.1% 20.3% 88.27%
1 Yr -5.5% -17.0% 25.9% 91.98%
3 Yr -19.2%* -30.0% 13.2% 97.42%
5 Yr N/A* -4.7% 16.0% 53.24%
10 Yr N/A* 0.4% 13.9% 75.63%

* Annualized

Return Ranking - Calendar

Period GERM Return Category Return Low Category Return High Rank in Category (%)
2023 -12.6% -12.6% 19.0% 100.00%
2022 -37.2% -53.9% 3.2% 96.77%
2021 14.6% -39.6% 24.2% 9.03%
2020 N/A -13.6% 178.2% N/A
2019 N/A 3.8% 63.8% N/A

Total Return Ranking - Trailing

Period GERM Return Category Return Low Category Return High Rank in Category (%)
YTD -1.4% -19.1% 20.3% 88.27%
1 Yr -5.5% -17.0% 25.9% 91.98%
3 Yr -19.2%* -30.0% 13.2% 97.42%
5 Yr N/A* -4.7% 16.0% N/A
10 Yr N/A* 0.4% 13.9% N/A

* Annualized

Total Return Ranking - Calendar

Period GERM Return Category Return Low Category Return High Rank in Category (%)
2023 -11.6% -12.6% 19.0% 98.15%
2022 -36.8% -53.9% 3.7% 96.77%
2021 14.9% -33.9% 26.0% 26.45%
2020 N/A -0.7% 180.6% N/A
2019 N/A 4.6% 63.8% N/A

GERM - Holdings

Concentration Analysis

GERM Category Low Category High GERM % Rank
Net Assets 11 M 7.41 M 47.2 B 90.12%
Number of Holdings 64 23 420 72.22%
Net Assets in Top 10 9.84 M 2.19 M 20.5 B 82.72%
Weighting of Top 10 76.97% 18.1% 77.0% 0.62%

Top 10 Holdings

  1. Mount Vernon Liquid Assets Portfolio, LLC 29.95%
  2. Moderna Inc 6.83%
  3. Alnylam Pharmaceuticals Inc 6.07%
  4. BioNTech SE 5.61%
  5. Laboratory Corp of America Holdings 5.59%
  6. Quest Diagnostics Inc 5.36%
  7. ImmunityBio Inc 4.85%
  8. Immunocore Holdings PLC 4.61%
  9. Vaxcyte Inc 4.31%
  10. QuidelOrtho Corp 3.81%

Asset Allocation

Weighting Return Low Return High GERM % Rank
Stocks
99.42% 87.17% 106.13% 24.07%
Cash
30.69% 0.00% 34.44% 1.85%
Convertible Bonds
0.33% 0.00% 0.37% 3.18%
Preferred Stocks
0.00% 0.00% 7.86% 88.27%
Other
0.00% -22.99% 23.31% 93.21%
Bonds
0.00% 0.00% 12.39% 85.80%

Stock Sector Breakdown

Weighting Return Low Return High GERM % Rank
Healthcare
100.00% 59.26% 100.00% 41.40%
Utilities
0.00% 0.00% 0.00% 84.08%
Technology
0.00% 0.00% 22.69% 84.08%
Real Estate
0.00% 0.00% 5.89% 85.99%
Industrials
0.00% 0.00% 7.02% 84.08%
Financial Services
0.00% 0.00% 1.60% 89.81%
Energy
0.00% 0.00% 0.00% 84.08%
Communication Services
0.00% 0.00% 9.11% 84.08%
Consumer Defense
0.00% 0.00% 25.73% 84.71%
Consumer Cyclical
0.00% 0.00% 1.92% 84.71%
Basic Materials
0.00% 0.00% 7.16% 87.90%

Stock Geographic Breakdown

Weighting Return Low Return High GERM % Rank
US
99.42% 66.21% 104.41% 17.90%
Non US
0.00% 0.00% 28.58% 95.68%

GERM - Expenses

Operational Fees

GERM Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.68% 0.08% 4.28% 77.78%
Management Fee 0.68% 0.03% 1.25% 51.23%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee N/A 0.03% 0.25% N/A

Sales Fees

GERM Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

GERM Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 1.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

GERM Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 39.00% 0.00% 238.00% 42.03%

GERM - Distributions

Dividend Yield Analysis

GERM Category Low Category High GERM % Rank
Dividend Yield 1.16% 0.00% 6.24% 24.07%

Dividend Distribution Analysis

GERM Category Low Category High Category Mod
Dividend Distribution Frequency Quarterly Annual Annual Annual

Net Income Ratio Analysis

GERM Category Low Category High GERM % Rank
Net Income Ratio 0.98% -2.54% 1.85% 6.45%

Capital Gain Distribution Analysis

GERM Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Semi-Annually Annually

Distributions History

View More +

GERM - Fund Manager Analysis

Managers

Devin Ryder


Start Date

Tenure

Tenure Rank

Jun 17, 2020

1.95

2.0%

Devin Ryder began her career with ETF Managers Group LLC during the summer of 2017 and re‑joined ETF Managers Group LLC on a permanent basis in 2018 to be a part of the portfolio management team. Prior to joining ETF Managers Group LLC, Ms. Ryder was pursuing studies in the quantitative aspects of risk management and finance, for which she received a B.S. in Mathematics of Finance and Risk Management from the University of Michigan in 2017.

Frank Vallario


Start Date

Tenure

Tenure Rank

Jun 17, 2020

1.95

2.0%

Frank Vallario serves in the role of Chief Investment Officer for the ETF Managers Group, LLC. Mr. Vallario is responsible for the portfolio construction, trading, risk management and portfolio analysis processes associated with ETF strategies. Prior to his current role, Mr. Vallario has had a variety of senior roles over his 25-year career in financial services. He joined Oppenheimer Funds in 2017 where he was Head of Equity Portfolio Management for Smart Beta ETFs. Prior to that he was Senior Portfolio Manager at Columbia Threadneedle from September 2015 to June 2017 where he was responsible for the day to day management of the firm’s ETF business, which was acquired from his previous firm, Emerging Global Advisors (EGA). From September 2010 to September 2015, he was relationship manager at MSCI responsible for providing investment solutions to complex problems using MSCI Barra’s fundamental models and portfolio construction tools. Previously, he was a partner in a start-up asset management firm where he served as the director of portfolio management. Mr. Vallario began his career at UBS Global Asset Management where he spent over a decade in various quantitative portfolio management equity roles including equity market neutral, tactical asset allocation, structured active equities, enhanced index, passive management and factor research. Mr. Vallario serves on the Investment Committee for the Girl Scouts of Connecticut and is a University Affiliate at the University of Utah - David Eccles School of Business. He received a B.S. in Finance from Lehigh University and a M.B.A. with a concentration in Finance from Rutgers University.

Samuel Masucci


Start Date

Tenure

Tenure Rank

Jun 17, 2020

1.95

2.0%

Samuel Masucci, III has more than 25 years’ experience in investment banking, structured product development, sales and trading. In the last 5 years, he founded ETF Managers Group (ETFMG) hich has led to the launch of 15 funds and $3 billion in assets. . Prior to ETFMG, Mr. Samuel Masucci, III has held senior positions at Bear Stearns, UBS, SBC Warburg, and Merrill Lynch and has experience in creating, building and managing businesses for the issuance, sales and trading of: ETFs, index products, commodity products, hedge funds, ABS, and OTC structured products in the U.S. and Europe.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.02 24.72 7.87 0.25